vs
AerSale Corp（ASLE）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是AerSale Corp的1.4倍（$127.1M vs $90.9M），再鼎医药同比增速更快（17.1% vs -4.0%），AerSale Corp自由现金流更多（$9.8M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 0.2%）
AerSale Corp总部位于美国佛罗里达州多拉市，是一家面向航空领域的全球供应商，主要为客运及货运航空公司、政府机构、跨国整机制造商与独立维修机构提供商用喷气飞机二手整机、发动机、航空耗材，并提供航空工程服务，同时该公司也是飞机机队回收协会的成员企业。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ASLE vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.4倍
$90.9M
营收增速更快
ZLAB
高出21.1%
-4.0%
自由现金流更多
ASLE
多$36.5M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $90.9M | $127.1M |
| 净利润 | $5.4M | — |
| 毛利率 | 34.1% | 51.0% |
| 营业利润率 | 7.8% | -54.6% |
| 净利率 | 5.9% | — |
| 营收同比 | -4.0% | 17.1% |
| 净利润同比 | 99.7% | — |
| 每股收益（稀释后） | $0.10 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASLEZLAB
| Q4 25 | $90.9M | $127.1M | ||
| Q3 25 | $71.2M | $115.4M | ||
| Q2 25 | $107.4M | $109.1M | ||
| Q1 25 | $65.8M | $105.7M | ||
| Q4 24 | $94.7M | $108.5M | ||
| Q3 24 | $82.7M | $101.8M | ||
| Q2 24 | $77.1M | $100.1M | ||
| Q1 24 | $90.5M | $87.1M |
净利润ASLEZLAB
| Q4 25 | $5.4M | — | ||
| Q3 25 | $-120.0K | $-36.0M | ||
| Q2 25 | $8.6M | $-40.7M | ||
| Q1 25 | $-5.3M | $-48.4M | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $509.0K | $-41.7M | ||
| Q2 24 | $-3.6M | $-80.3M | ||
| Q1 24 | $6.3M | $-53.5M |
毛利率ASLEZLAB
| Q4 25 | 34.1% | 51.0% | ||
| Q3 25 | 30.2% | 59.5% | ||
| Q2 25 | 32.9% | 60.6% | ||
| Q1 25 | 27.3% | 63.6% | ||
| Q4 24 | 31.4% | 61.5% | ||
| Q3 24 | 28.6% | 64.1% | ||
| Q2 24 | 28.2% | 64.9% | ||
| Q1 24 | 31.8% | 61.4% |
营业利润率ASLEZLAB
| Q4 25 | 7.8% | -54.6% | ||
| Q3 25 | 4.0% | -42.3% | ||
| Q2 25 | 11.7% | -50.3% | ||
| Q1 25 | -10.1% | -53.3% | ||
| Q4 24 | 5.2% | -62.6% | ||
| Q3 24 | 2.4% | -66.6% | ||
| Q2 24 | -2.4% | -76.0% | ||
| Q1 24 | 5.2% | -80.7% |
净利率ASLEZLAB
| Q4 25 | 5.9% | — | ||
| Q3 25 | -0.2% | -31.2% | ||
| Q2 25 | 8.0% | -37.3% | ||
| Q1 25 | -8.0% | -45.8% | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 0.6% | -40.9% | ||
| Q2 24 | -4.7% | -80.2% | ||
| Q1 24 | 6.9% | -61.4% |
每股收益（稀释后）ASLEZLAB
| Q4 25 | $0.10 | $-0.05 | ||
| Q3 25 | $0.00 | $-0.03 | ||
| Q2 25 | $0.18 | $-0.04 | ||
| Q1 25 | $-0.10 | $-0.04 | ||
| Q4 24 | $0.05 | $-0.09 | ||
| Q3 24 | $0.01 | $-0.04 | ||
| Q2 24 | $-0.07 | $-0.08 | ||
| Q1 24 | $0.12 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.4M | $689.6M |
| 总债务越低越好 | $1.3M | — |
| 股东权益账面价值 | $424.4M | $715.5M |
| 总资产 | $640.5M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资ASLEZLAB
| Q4 25 | $4.4M | $689.6M | ||
| Q3 25 | $5.3M | $717.2M | ||
| Q2 25 | $5.7M | $732.2M | ||
| Q1 25 | $4.7M | $757.3M | ||
| Q4 24 | $4.7M | $779.7M | ||
| Q3 24 | $9.8M | $616.1M | ||
| Q2 24 | $4.3M | $630.0M | ||
| Q1 24 | $2.6M | $650.8M |
总债务ASLEZLAB
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $907.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $376.0K | — | ||
| Q2 24 | $522.0K | — | ||
| Q1 24 | $3.5M | — |
股东权益ASLEZLAB
| Q4 25 | $424.4M | $715.5M | ||
| Q3 25 | $417.1M | $759.9M | ||
| Q2 25 | $415.9M | $791.7M | ||
| Q1 25 | $406.5M | $810.8M | ||
| Q4 24 | $455.6M | $840.9M | ||
| Q3 24 | $451.5M | $667.7M | ||
| Q2 24 | $449.8M | $704.2M | ||
| Q1 24 | $452.0M | $762.2M |
总资产ASLEZLAB
| Q4 25 | $640.5M | $1.2B | ||
| Q3 25 | $646.3M | $1.2B | ||
| Q2 25 | $646.7M | $1.2B | ||
| Q1 25 | $646.1M | $1.2B | ||
| Q4 24 | $604.7M | $1.2B | ||
| Q3 24 | $601.5M | $985.3M | ||
| Q2 24 | $598.7M | $987.4M | ||
| Q1 24 | $571.7M | $988.4M |
负债/权益比ASLEZLAB
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $9.8M | $-26.7M |
| 自由现金流率自由现金流/营收 | 10.8% | -21.0% |
| 资本支出强度资本支出/营收 | 1.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.11× | — |
| 过去12个月自由现金流最近4个季度 | $-29.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ASLEZLAB
| Q4 25 | $11.4M | $-26.0M | ||
| Q3 25 | $-8.9M | $-32.0M | ||
| Q2 25 | $19.8M | $-31.0M | ||
| Q1 25 | $-45.2M | $-61.7M | ||
| Q4 24 | $37.5M | $-55.8M | ||
| Q3 24 | $10.4M | $-26.8M | ||
| Q2 24 | $-15.3M | $-42.2M | ||
| Q1 24 | $-21.5M | $-90.1M |
自由现金流ASLEZLAB
| Q4 25 | $9.8M | $-26.7M | ||
| Q3 25 | $-9.8M | $-35.0M | ||
| Q2 25 | $18.6M | $-33.9M | ||
| Q1 25 | $-47.6M | $-63.2M | ||
| Q4 24 | $32.3M | $-58.4M | ||
| Q3 24 | $8.9M | $-28.2M | ||
| Q2 24 | $-18.9M | $-42.9M | ||
| Q1 24 | $-25.0M | $-91.1M |
自由现金流率ASLEZLAB
| Q4 25 | 10.8% | -21.0% | ||
| Q3 25 | -13.8% | -30.4% | ||
| Q2 25 | 17.3% | -31.1% | ||
| Q1 25 | -72.4% | -59.9% | ||
| Q4 24 | 34.0% | -53.8% | ||
| Q3 24 | 10.7% | -27.7% | ||
| Q2 24 | -24.6% | -42.9% | ||
| Q1 24 | -27.7% | -104.5% |
资本支出强度ASLEZLAB
| Q4 25 | 1.7% | 0.5% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 3.7% | 1.5% | ||
| Q4 24 | 5.6% | 2.4% | ||
| Q3 24 | 1.9% | 1.3% | ||
| Q2 24 | 4.7% | 0.7% | ||
| Q1 24 | 3.9% | 1.1% |
现金转化率ASLEZLAB
| Q4 25 | 2.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.89× | — | ||
| Q3 24 | 20.52× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -3.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
